S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Dozens of animals taken from Virginia roadside zoo as part of investigation
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
New CBOE “special perk” helps traders target income every weekend (Ad)
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
Consumer product agency issues warning on small magnetic balls linked to deaths

Progyny (PGNY) Stock Forecast & Price Target

$36.26
-0.05 (-0.14%)
(As of 12/8/2023 ET)
Compare
Today's Range
$36.06
$36.96
50-Day Range
$29.51
$36.45
52-Week Range
$28.03
$44.95
Volume
590,832 shs
Average Volume
720,179 shs
Market Capitalization
$3.48 billion
P/E Ratio
69.73
Dividend Yield
N/A
Price Target
$47.00

Progyny Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$47.00
29.62% Upside
High Forecast$57.00
Average Forecast$47.00
Low Forecast$34.00
TypeCurrent Forecast
12/9/22 to 12/9/23
1 Month Ago
11/9/22 to 11/9/23
3 Months Ago
9/10/22 to 9/10/23
1 Year Ago
12/9/21 to 12/9/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.00$47.00$49.00$57.67
Predicted Upside29.62% Upside38.82% Upside35.52% Upside51.90% Upside
Get Progyny Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.


PGNY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PGNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Progyny Stock vs. The Competition

TypeProgynyMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside29.62% Upside736.38% Upside3,819.09% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/8/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$52.00 ➝ $47.00+50.26%
11/8/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$50.00 ➝ $45.00+40.62%
10/9/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$58.00 ➝ $57.00+69.69%
9/27/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$46.00+34.46%
9/14/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$45.00 ➝ $48.00+35.98%
5/22/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$50.00+34.66%
5/9/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$48.00 ➝ $50.00+32.03%
1/5/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$59.00 ➝ $34.00+9.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:41 AM ET.












PGNY Price Target - Frequently Asked Questions

What is Progyny's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Progyny stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for PGNY. The average twelve-month price prediction for Progyny is $47.00 with a high price target of $57.00 and a low price target of $34.00. Learn more on PGNY's analyst rating history.

Do Wall Street analysts like Progyny more than its competitors?

Analysts like Progyny more than other Medical companies. The consensus rating score for Progyny is 2.88 while the average consensus rating score for medical companies is 2.68. Learn more on how PGNY compares to other companies.

Does Progyny's stock price have much upside?

According to analysts, Progyny's stock has a predicted upside of 38.82% based on their 12-month stock forecasts.

What analysts cover Progyny?

Stock Ratings Reports and Tools

This page (NASDAQ:PGNY) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -